Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285087285> ?p ?o ?g. }
- W4285087285 endingPage "1491" @default.
- W4285087285 startingPage "1476" @default.
- W4285087285 abstract "Given that only a subset of patients with glioblastoma multiforme (GBM) responds to immuno-oncology, this study aimed to assess the impact of multiple factors on GBM immunotherapy prognosis and investigate the potential predictors.A quantitative meta-analysis was conducted using the random-effects model. Several potential factors were also reviewed qualitatively.A total of 39 clinical trials were included after screening 1317 papers. Patients with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation [hazard ratio (HR) for overall survival (OS) = 2.30, p < 0.0001; HR for progression-free survival (PFS) = 2.10, p < 0.0001], gross total resection (HR for OS = 0.70, p = 0.02; HR for PFS = 0.56, p = 0.004), and no baseline steroid use (HR for OS = 0.52, p = 0.0002; HR for PFS = 0.61, p = 0.02) had a relatively significant favorable OS and PFS following immunotherapy. Patients with a Karnofsky Performance Status score < 80 (HR = 1.73, p = 0.0007) and undergoing two prior relapses (HR = 2.08, p = 0.003) were associated with worse OS. Age, gender, tumor programmed death-ligand 1 expression, and history of chemotherapy were not associated with survival outcomes. Notably, immunotherapy significantly improved the OS among patients undergoing two prior recurrences (HR = 0.40, p = 0.008) but not among patients in any other subgroups, as opposed to non-immunotherapy.Several factors were associated with prognostic outcomes of GBM patients receiving immunotherapy; multiple recurrences might be a candidate predictor. More marker-driven prospective studies are warranted." @default.
- W4285087285 created "2022-07-14" @default.
- W4285087285 creator A5048612706 @default.
- W4285087285 creator A5057762207 @default.
- W4285087285 creator A5066222509 @default.
- W4285087285 creator A5068444891 @default.
- W4285087285 creator A5088025197 @default.
- W4285087285 date "2022-07-13" @default.
- W4285087285 modified "2023-10-15" @default.
- W4285087285 title "Impact of molecular and clinical variables on survival outcome with immunotherapy for glioblastoma patients: A systematic review and meta‐analysis" @default.
- W4285087285 cites W1513125948 @default.
- W4285087285 cites W1533046157 @default.
- W4285087285 cites W1580148418 @default.
- W4285087285 cites W1607316259 @default.
- W4285087285 cites W1815157104 @default.
- W4285087285 cites W1977142594 @default.
- W4285087285 cites W1986822378 @default.
- W4285087285 cites W1995172058 @default.
- W4285087285 cites W2005518401 @default.
- W4285087285 cites W2009720434 @default.
- W4285087285 cites W2017044005 @default.
- W4285087285 cites W2020604769 @default.
- W4285087285 cites W2033585778 @default.
- W4285087285 cites W2049092411 @default.
- W4285087285 cites W2056679169 @default.
- W4285087285 cites W2072838309 @default.
- W4285087285 cites W2075137177 @default.
- W4285087285 cites W2082226454 @default.
- W4285087285 cites W2088095316 @default.
- W4285087285 cites W2105100844 @default.
- W4285087285 cites W2106623789 @default.
- W4285087285 cites W2107328434 @default.
- W4285087285 cites W2116371946 @default.
- W4285087285 cites W2124736921 @default.
- W4285087285 cites W2125435699 @default.
- W4285087285 cites W2126834976 @default.
- W4285087285 cites W2131981377 @default.
- W4285087285 cites W2133499518 @default.
- W4285087285 cites W2134754781 @default.
- W4285087285 cites W2135947790 @default.
- W4285087285 cites W2136859769 @default.
- W4285087285 cites W2137605317 @default.
- W4285087285 cites W2137930630 @default.
- W4285087285 cites W2141713308 @default.
- W4285087285 cites W2143753538 @default.
- W4285087285 cites W2146881779 @default.
- W4285087285 cites W2148977460 @default.
- W4285087285 cites W2157823046 @default.
- W4285087285 cites W2158681922 @default.
- W4285087285 cites W2161374186 @default.
- W4285087285 cites W2162630386 @default.
- W4285087285 cites W2165114272 @default.
- W4285087285 cites W2165871546 @default.
- W4285087285 cites W2168718800 @default.
- W4285087285 cites W2205491921 @default.
- W4285087285 cites W2295482860 @default.
- W4285087285 cites W2303158491 @default.
- W4285087285 cites W2410468716 @default.
- W4285087285 cites W2508076331 @default.
- W4285087285 cites W2519740810 @default.
- W4285087285 cites W2524525752 @default.
- W4285087285 cites W2527876252 @default.
- W4285087285 cites W2559382297 @default.
- W4285087285 cites W2580803528 @default.
- W4285087285 cites W2588896788 @default.
- W4285087285 cites W2590231577 @default.
- W4285087285 cites W2591716768 @default.
- W4285087285 cites W2600281432 @default.
- W4285087285 cites W2606625852 @default.
- W4285087285 cites W2613340520 @default.
- W4285087285 cites W2738678436 @default.
- W4285087285 cites W2748739447 @default.
- W4285087285 cites W2749747068 @default.
- W4285087285 cites W2772664652 @default.
- W4285087285 cites W2792153970 @default.
- W4285087285 cites W2796584001 @default.
- W4285087285 cites W2797675588 @default.
- W4285087285 cites W2801173377 @default.
- W4285087285 cites W2805359783 @default.
- W4285087285 cites W2811300508 @default.
- W4285087285 cites W2885696745 @default.
- W4285087285 cites W2886389565 @default.
- W4285087285 cites W2886443268 @default.
- W4285087285 cites W2888273332 @default.
- W4285087285 cites W2888502795 @default.
- W4285087285 cites W2888599070 @default.
- W4285087285 cites W2896671924 @default.
- W4285087285 cites W2900082702 @default.
- W4285087285 cites W2902462978 @default.
- W4285087285 cites W2902596375 @default.
- W4285087285 cites W2911752971 @default.
- W4285087285 cites W2911871569 @default.
- W4285087285 cites W2913486358 @default.
- W4285087285 cites W2913623258 @default.
- W4285087285 cites W2916332433 @default.
- W4285087285 cites W2947762281 @default.
- W4285087285 cites W2963298763 @default.
- W4285087285 cites W2970684805 @default.